{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:39:51Z","timestamp":1792237191996,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1736,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1124\/dmd.119.089003","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T06:55:14Z","timestamp":1580712914000},"page":"307-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations"],"prefix":"10.1016","volume":"48","author":[{"given":"Aarti","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal S.","family":"Taskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tracey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Riddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Marotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith M.","family":"Hessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.119.089003_bib1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/toxsci\/57.2.312","article-title":"Application of a hybrid CFD-PBPK nasal dosimetry model in an inhalation risk assessment: an example with acrylic acid","volume":"57","author":"Andersen","year":"2000","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.119.089003_bib2","first-page":"1","article-title":"Dosimetry software to predict particle deposition in humans and rats","volume":"19","author":"Asgharian","year":"1999","journal-title":"CIIT Activities"},{"key":"10.1124\/dmd.119.089003_bib3","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaerosci.2006.01.002","article-title":"Prediction of particle deposition in the human lung using realistic models of lung ventilation","volume":"37","author":"Asgharian","year":"2006","journal-title":"J Aerosol Sci"},{"key":"10.1124\/dmd.119.089003_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","article-title":"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin","volume":"54","author":"Backman","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.119.089003_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1124\/jpet.118.255109","article-title":"Relationship between pharmacokinetics and pharmacodynamic responses in healthy smokers informs a once-daily dosing regimen for nemiralisib","volume":"369","author":"Begg","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.089003_bib6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/17425255.2013.781582","article-title":"Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations","volume":"9","author":"Bloomer","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.119.089003_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2017.1436","article-title":"Physiologically based pharmacokinetic\/pharmacodynamic modeling accurately predicts the better bronchodilatory effect of inhaled versus oral salbutamol dosage forms","volume":"32","author":"Boger","year":"2019","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1124\/dmd.119.089003_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/psp4.12344","article-title":"A partial differential equation approach to inhalation physiologically based pharmacokinetic modeling","volume":"7","author":"Boger","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.119.089003_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1208\/s12248-015-9760-6","article-title":"Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs","volume":"17","author":"Borghardt","year":"2015","journal-title":"AAPS J"},{"key":"10.1124\/dmd.119.089003_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pupt.2017.08.008","article-title":"Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3K\u03b4 inhibitor under development for the treatment of COPD","volume":"46","author":"Cahn","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/dmd.119.089003_bib11","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1021\/acs.jmedchem.5b00767","article-title":"Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase \u03b4 for the treatment of respiratory disease","volume":"58","author":"Down","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.119.089003_bib12","series-title":"Guideline on the Investigation of Drug Interactions, CPMP\/EWP\/560\/95\/Rev. 1 Corr. 2","author":"European Medicines","year":"2012"},{"key":"10.1124\/dmd.119.089003_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1468-1293.2008.00579.x","article-title":"Adrenal suppression and Cushing\u2019s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature","volume":"9","author":"Foisy","year":"2008","journal-title":"HIV Med"},{"key":"10.1124\/dmd.119.089003_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","article-title":"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin","volume":"64","author":"Gorski","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.089003_bib15","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1124\/dmd.119.088344","article-title":"An innovative approach to characterize clinical ADME and pharmacokinetics of the inhaled drug nemiralisib using an intravenous microtracer combined with an inhaled dose and an oral radiolabel dose in healthy male subjects","volume":"47","author":"Harrell","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.089003_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/clpt.2014.41","article-title":"Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies","volume":"95","author":"Ke","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.089003_bib17","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/bcp.12019","article-title":"The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects","volume":"75","author":"Kempsford","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.119.089003_bib18","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1124\/dmd.114.057778","article-title":"The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk","volume":"42","author":"Lawrence","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.089003_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ecoenv.2018.10.091","article-title":"Application of multiple-path particle dosimetry model for quantifying age specified deposition of particulate matter in human airway","volume":"168","author":"Manojkumar","year":"2019","journal-title":"Ecotoxicol Environ Saf"},{"key":"10.1124\/dmd.119.089003_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.089003_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.1013","article-title":"Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective","volume":"104","author":"Shebley","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.089003_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/clpt.1988.108","article-title":"Effect of calcium channel blockers on theophylline disposition","volume":"44","author":"Sirmans","year":"1988","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.119.089003_bib22","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1124\/dmd.107.015966","article-title":"A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes","volume":"35","author":"Somers","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.119.089003_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02280751","article-title":"The effect of three different oral doses of verapamil on the disposition of theophylline","volume":"43","author":"Stringer","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.119.089003_bib24","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0022-3565(25)12414-2","article-title":"Theophylline metabolism in human liver microsomes: inhibition studies","volume":"276","author":"Tjia","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.119.089003_bib25","series-title":"Drug Interaction Studies \u2013 Study Design, Data Analysis and Implications for Dosing and Labelling, Draft Guidance","year":"2006"},{"key":"10.1124\/dmd.119.089003_bib26","series-title":"Clinical Drug Interaction Studies - Study Design, Data Analysis, and Clinical Implications, Guidance for Industry, Draft Guidance","year":"2017"},{"key":"10.1124\/dmd.119.089003_bib27","series-title":"In Vitro Metabolism and Transport-Mediated Drug-Drug Interaction Studies, Guidance for Industry, Draft Guidance","year":"2017"},{"key":"10.1124\/dmd.119.089003_bib28","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.clinthera.2018.06.011","article-title":"Safety, tolerability, and pharmacokinetics of single and repeat doses of nemiralisib administered via the Ellipta dry powder inhaler to healthy subjects","volume":"40","author":"Wilson","year":"2018","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.119.089003_bib29","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.clinthera.2019.04.008","article-title":"Safety, tolerability, and pharmacokinetics of a new formulation of nemiralisib administered via a dry powder inhaler to healthy individuals","volume":"41","author":"Wilson","year":"2019","journal-title":"Clin Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.119.089003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T12:51:26Z","timestamp":1740055886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624080061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0090955624080061"],"URL":"https:\/\/doi.org\/10.1124\/dmd.119.089003","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.119.089003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s)","name":"copyright","label":"Copyright"}]}}